AbbVie Inc. (ABBV) Stock Forecast
ABBV analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.30 / 5 from 30 analysts
- Price target
- $282.61 average of analyst targets
- Upside to target
- −1.0% from the latest close
- Next earnings
- October 30, 2026 EPS estimate $3.76
- 52-week range
- $197.38 – $285.42
ABBV analyst ratings
30 analystsNumber of analysts at each rating.
ABBV price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ABBV earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $3.79 | $3.61 | $3.86 | $1.86 | +103.6% | 21 |
| Current fiscal year (2026) | $13.96 | $13.81 | $14.25 | $10.00 | +39.6% | 27 |
| Next fiscal year (2027) | $16.21 | $15.13 | $17.65 | $13.96 | +16.1% | 24 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ABBV revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $17.35B | $17.20B | $17.58B | +10.0% | 20 |
| Current fiscal year (2026) | $67.62B | $67.11B | $67.99B | +10.6% | 24 |
| Next fiscal year (2027) | $73.57B | $70.91B | $75.00B | +8.8% | 21 |
ABBV EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ABBV revenue: reported and forecast
ABBV EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $3.85 | $3.84 | $3.84 | $3.80 | $3.79 | −1.5% | 0 up · 8 down |
| Current fiscal year (2026) | $14.18 | $14.01 | $14.01 | $13.98 | $13.96 | −1.5% | 0 up · 10 down |
| Next fiscal year (2027) | $16.33 | $16.28 | $16.27 | $16.25 | $16.21 | −0.7% | 3 up · 6 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ABBV earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ABBV beat in 10 of 12.
What analysts expect from ABBV
30 analysts cover AbbVie; their consensus rating is buy (4.30 on a 1–5 scale, where 5 is a strong buy). The average price target is $282.61, 1.0% below the latest close of $285.42. Analysts expect earnings of $13.96 per share for 2026, +39.6% from a year earlier. For 2027 the average estimate is $16.21 per share on revenue of $73.6 billion. AbbVie beat the EPS estimate in 10 of the last 12 quarters.
Related: ABBV income statement, ABBV key metrics, ABBV chart. See the ABBV stock overview for the latest quote and news.
ABBV forecast FAQ
What is AbbVie's price target?
The average analyst price target for AbbVie is $282.61, 1.0% below the latest close of $285.42.
Is AbbVie a buy, hold or sell?
Of 30 analysts covering AbbVie, 16 rate it a strong buy, 8 a buy, 5 a hold, 1 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is AbbVie's EPS forecast?
Analysts forecast $13.96 per share for 2026 (range $13.81 to $14.25); for 2027 the estimate is $16.21.
What is AbbVie's revenue forecast?
The average revenue estimate for 2026 is $67.6 billion, growth of 10.6%; for 2027 it is $73.6 billion.
When does AbbVie report earnings?
AbbVie is expected to report results for the quarter ending September 30, 2026 on October 30, 2026 before the market opens; the EPS estimate is $3.76.
Does AbbVie usually beat earnings estimates?
AbbVie reported EPS at or above the analyst estimate in 10 of the last 12 quarters.